The Ohio State University Comprehensive Cancer Center, Columbus, OH
Shawn Dason , Tyler Sheetz , Shagnik Ray , Danielle Elise Zimmerman , Ming Yin , Edmund Folefac , Amir Mortazavi , Michael Gong , Ahmad Shabsigh , Eric A. Singer
Background: Management of metastatic renal cell carcinoma (mRCC) is highly individualized and often involves cytoreductive nephrectomy (CN) and systemic therapy (ST). The optimal sequencing of CN and ST is uncertain. A difference in perioperative outcomes based on sequence of CN and ST could influence decision-making. We conducted this NSQIP analysis to assess whether preoperative systemic therapy adversely impacted perioperative outcomes in patients receiving deferred CN. Methods: This analysis was conducted using the American College of Surgeons NSQIP Participant Use Data File for years 2019 and 2020. These years were selected because data on receipt of preoperative therapy is only available since 2019. Inclusion criteria were i) CPT code consistent with nephrectomy, ii) urologist operating surgeon & iii) presence of disseminated cancer. All cases with ICD-10 diagnosis codes not consistent with mRCC were excluded. Groups were stratified by their receipt of preoperative systemic therapy within 90 days before CN and we assessed 46 preoperative and perioperative outcomes. Results: The study cohort included 505 patients with 115 (23%) who received preoperative ST. No differences were noted in perioperative outcomes (Table). Patients receiving preoperative ST were more likely to be on steroids (23% vs. 7%, p<0.01) and develop urinary tract infections (4.3% vs. 0.5%, p<0.01). There were no significant differences noted in other related variables like surgical site infections, wound dehiscence, sepsis, septic shock, pneumonia, cardiovascular complications, preoperative hypertension, or preoperative diabetes (p>0.05). Conclusions: Because preoperative ST did not have an appreciable impact on deferred CN perioperative outcomes, decision making for ST and CN sequencing should not be influenced by perioperative outcomes. Those who undergo deferred CN are unlikely to experience delayed time to surgery or perioperative complications from their ST.
No Preoperative Systemic Therapy (n=390) | Preoperative Systemic Therapy (n=115) | p-value | |
---|---|---|---|
Mortality (% in 30 days) | 2.8% | 0.9% | 0.3 |
Readmission (% in 30 days) | 8.5% | 8.7% | 0.9 |
Return to OR (% in 30 days) | 1.8% | 4.3% | 0.1 |
Mean operative time, minutes (SD) | 198 (116) | 212 (116) | 0.3 |
Mean postoperative hospital stay, days (SD) | 4.2 (4.2) | 3.7 (3.0) | 0.3 |
Minimally-invasive converted to open rate (%)* | 2.6% | 1.7% | 0.2 |
Discharge to home** (%) | 92.6% | 96.5% | 0.9 |
Remaining in hospital >30 days (%) | 0.8% | 0.0% | 0.3 |
OR - operating room, SD - standard deviation, *for planned minimally-invasive procedures, **vs. another non-hospital facility.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Genitourinary Cancers Symposium
First Author: Abhenil Mittal
2024 ASCO Genitourinary Cancers Symposium
First Author: Dimitrios Makrakis
2021 ASCO Annual Meeting
First Author: Pooja Ghatalia
2021 Genitourinary Cancers Symposium
First Author: Jigi Moudgil-Joshi